By Tokio X'press Alzheimer, FDA, Medical science, Pharmaceutical
Selling price for Lecanemab: $26,500 per patient per year!
US FDA: Takeda Pharmaceutical’s Lung Cancer Treatment Approval: Exkivity
COVID-19: FDA grants “Actemra” urgently: reduces mortality
Massive WHO remdesivir study suggests no Covid-19 benefit
COVID-19: EU, Remdesivir supply contract: need to be reviewed?